Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: paindiabeticplaceborandomizationneuropathy
  Phrases that lowered it: subjectsscreeningmaleagedinclusive
• Sponsor's past termination rate: 9.0% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 5.2% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 70.7% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 57 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: not given (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 15637 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Blinding: double (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy NCT01057693 · started 2010 · scored riskier than 30% of active trials completed
• Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) NCT01474772 · started 2011 · scored riskier than 31% of active trials completed
• The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy NCT02927951 · started 2011 · scored riskier than 87% of active trials completed
• Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain NCT01455415 · started 2011 · scored riskier than 37% of active trials completed
• Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability NCT01928381 · started 2013 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.